Mucinous Epithelial Ovarian Cancer Treatment and Follow-up Pathway Map
Version 2020.01

Disclaimer
The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Ontario Health (Cancer Care Ontario) and the reader.
Target Population

- Women presenting with epithelial ovarian cancer

Pathway Map Considerations

- For more information about the optimal organization of gynecologic oncology services in Ontario refer to EBS #4-11
- The staging system used throughout the Ovarian Cancer Treatment Pathway is the 2014 FIGO staging system.
- Primary care providers play an important role in the cancer journey and should be informed of relevant tests and consultations. Ongoing care with a primary care provider is assumed to be part of the pathway map. For patients who do not have a primary care provider, Health Care Connect is a government resource that helps patients find a doctor or nurse practitioner.
- Throughout the pathway map, a shared decision-making model should be implemented to enable and encourage patients to play an active role in the management of their care. For more information see Person-Centered Care Guideline and EBS #19-2 Provider-Patient Communication.
- Hyperlinks are used throughout the pathway map to provide information about relevant Ontario Health (Cancer Care Ontario) tools, resources and guidance documents.
- The term ‘healthcare provider’, used throughout the pathway map, includes primary care providers and specialists, e.g. family doctors, nurse practitioners, gynecologists, midwives and emergency physicians.
- For more information on Multidisciplinary Cancer Conferences visit MCC Tools.
- For more information on wait time prioritization, visit Surgery.
- Clinical trials should be considered for all phases of the pathway map.
- Psychosocial oncology (PSO) is the interprofessional specialty concerned with understanding and treating the social, practical, psychological, emotional, spiritual and functional needs and quality-of-life impact that cancer has on patients and their families. Psychosocial care should be considered an integral and standardized part of cancer care for patients and their families at all stages of the illness trajectory. For more information, visit EBS #19-2.
- The following should be considered when weighing the treatment options described in this pathway map for patients with potentially life-limiting illness:
  - Palliative care may be of benefit at any stage of the cancer journey, and may enhance other types of care – including restorative or rehabilitative care – or may become the total focus of care
  - Ongoing discussions regarding goals of care is central to palliative care, and is an important part of the decision-making process. Goals of care discussions include the type, extent and goal of a treatment or care plan, where care will be provided, which health care providers will provide the care, and the patient’s overall approach to care

Pathway Map Disclaimer

This pathway map is a resource that provides an overview of the treatment that an individual in the Ontario cancer system may receive.

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if she/he has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Ontario Health (Cancer Care Ontario) and the reader.

While care has been taken in the preparation of the information contained in the pathway map, such information is provided on an "as-is" basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability. Ontario Health (Cancer Care Ontario) and the pathway map’s content providers (including the physicians who contributed to the information in the pathway map) shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the pathway map or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the pathway map does so at his or her own risk, and by using such information, agrees to indemnify Ontario Health (Cancer Care Ontario) and its content providers from and against any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the pathway map.

This pathway map may not reflect all the available scientific research and is not intended as an exhaustive resource. Ontario Health (Cancer Care Ontario) and its content providers assume no responsibility for omissions or incomplete information in this pathway map. It is possible that other relevant scientific findings may have been reported since completion of this pathway map. This pathway map may be superseded by an updated pathway map on the same topic.

© Ontario Health (Cancer Care Ontario) retains all copyright, trademark and all other rights in the pathway map, including all text and graphic images. No portion of this pathway map may be used or reproduced, other than for personal use, or distributed, transmitted or "mirrored" in any form, or by any means, without the prior written permission of Ontario Health (Cancer Care Ontario).

Note: EBS #19-2 and EBS #19-3 are older than 3 years and are currently listed as ‘For Education and Information Purposes’. This means that the recommendations will no longer be maintained but may still be useful for academic or other information purposes.
Suspicious Pelvic Mass with No Tissue Diagnosis, Presumed Clinical Early Stage

Mucinous Epithelial Ovarian Cancer Treatment and Follow-up Pathway Map

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map.

The information in the pathway map does not create a physician-patient relationship between Ontario Health (Cancer Care Ontario) and the reader.

The pathway is intended to be used for informational purposes only. The pathway is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Ontario Health (Cancer Care Ontario) and the reader.

Screen for psychosocial needs, and assessment and management of symptoms. Click here for more information about symptom assessment and management tools.

Consider the introduction of palliative care, early and across the cancer journey. Click here for more information about palliative care.

1 Discussion to be individualized for each patient; however, may include the following: age, fertility preservation, hormone replacement therapy, referral for infertility consultation, etc.
2 Pathologists with a specialty or special interest in gynecologic pathology.
3 If appropriate, the option of fertility sparing surgery should be discussed with the patient.
Mucinous Epithelial Ovarian Cancer Treatment and Follow-up Pathway Map

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Ontario Health (Cancer Care Ontario) and the reader.

Screen for psychosocial needs, and assessment and management of symptoms. Click here for more information about symptom assessment and management tools

Consider the introduction of palliative care, early and across the cancer journey. Click here for more information about palliative care

1 Discussion to be individualized for each patient; however, may include the following: age, fertility preservation, hormone replacement therapy, referral for infertility consultation, etc.

2 If appropriate, the option of fertility sparing surgery should be discussed with the patient.
Screen for psychosocial needs, and assessment and management of symptoms. Click here for more information about symptom assessment and management tools.

Consider the introduction of palliative care, early and across the cancer journey. Click here for more information about palliative care.
Mucinous Epithelial Ovarian Cancer Treatment and Follow-up Pathway Map

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Ontario Health (Cancer Care Ontario) and the reader.

Screen for psychosocial needs, and assessment and management of symptoms. Click here for more information about symptom assessment and management tools

Consider the introduction of palliative care, early and across the cancer journey. Click here for more information about palliative care

From Diagnosis Pathway (Page 3)

From Page 4

Advanced Stage

Pathologist

Primary Cytoreductive Surgery
- Bilateral Salpingo-oophorectomy
- Total Hysterectomy
- Possible Cytoreductive Surgery
- Appendectomy

Pathologist

EBS #4-15

Mucinous neoplasm

Suspicion of non-gynecological primary

Intraoperative Surgical Oncologist

Clinical Trials
- EBS #4-3

Or

Intravenous Systemic Therapy
- EBS #4-3

Psychosocial oncology and supportive care
Referral to appropriate specialist if additional support is required

End of life care planning

Progression

No Visible Residual Disease

Proceed to Page 7

Visible Residual Disease

Proceed to Page 7

End of life care

MCC

Palliative Care

Medical Oncologist

Pathologist

EGFR

Biopsy

If not previously done

Not appropriate for surgery

Upper GI Endoscopy

Colonoscopy

Blood Tests
- CEA
- CA 19-9
- CA-125

F

B

D

Imaging and GI Evaluation
(if not already performed)

CT Abdomen Pelvis

CT Chest

Sexual Health and Fertility Discussion

Gynecologic Oncologist

Screen for psychosocial needs, and assessment and management of symptoms. Click here for more information about symptom assessment and management tools

Consider the introduction of palliative care, early and across the cancer journey. Click here for more information about palliative care

From Page 4

From Page 3

Discussion to be individualized for each patient; however, may include the following: age, fertility preservation, hormone replacement therapy, referral for infertility consultation, etc.

To determine the appropriateness for surgery, the following should be taken into consideration: performance status, response to chemotherapy, surgical resectability, and patient comorbidities

When available, clinical trials are to be a priority in this patient population


Consider addition of Bevacizumab for front line treatment of ovarian cancer: 1) stage III suboptimally debulked; 2) stage III unresectable; 3) stage IV. Refer to Ontario Health (Cancer Care Ontario) appropriate Bevacizumab Eligibility Form
Mucinous Epithelial Ovarian Cancer Treatment and Follow-up Pathway Map

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway maps. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Ontario Health (Cancer Care Ontario) and the reader.

Screen for psychosocial needs, and assessment and management of symptoms. Click here for more information about symptom assessment and management tools

Consider the introduction of palliative care, early and across the cancer journey Click here for more information about palliative care

---

1 When available, clinical trials are to be a priority in this patient population

2 Consider addition of Bevacizumab for front line treatment of ovarian cancer: 1) stage III suboptimally debulked; 2) stage III unresectable; 3) stage IV. Refer to Ontario Health (Cancer Care Ontario) for appropriate Bevacizumab Eligibility Form
Follow-Up Care

Follow-Up Care

follow-up and surveillance

Every 3 to 6 months (Year 1 and 2)
Every 6 to 12 months (Year 3 to 5)
then annually*

patients who have completed primary treatment and who are without evidence of disease

physical exam and full pelvic examination

blood test may include:
- CA 125
- other tests as clinically indicated

Suspect of progression

CT Abdomen Pelvis
CT Chest
Chest X-ray
Blood test to include CA 125

Results

Progression

No Progression

Proceed to Page 9

Annual follow-up by gynecologist, family doctor or gynecologic oncologist.

* Annual follow-up by gynecologist, family doctor or gynecologic oncologist.
Screen for psychosocial needs, and assessment and management of symptoms. [Click here for more information about symptom assessment and management tools]

Consider the introduction of palliative care, early and across the cancer journey [Click here for more information about palliative care]

When available, clinical trials are to be a priority in this patient population
Pathway Map Target Population:
Individuals with cancer approaching the last 3 months of life and their families.

While this section of the pathway is focused on the care delivered at the end of life, palliative care should be initiated much earlier in the illness trajectory. In particular, providers can introduce a palliative approach to care as early as the time of diagnosis.

### Triggers that suggest patients are nearing the last few months and weeks of life
- ECOG/Patient-ECOG/PRFS ≤ 4
- PPS ≤ 50
- Declining performance status/functional ability

### End of Life Care planning and implementation
- Collaboration and consultation between specialist-level care teams and primary care teams

### Screen, Assess, Plan, Manage and Follow-Up
- Conversations to determine where care should be provided, and who will be responsible for providing the care

---

### End of Life Care

<table>
<thead>
<tr>
<th>Key conversations to revisit Goals of Care and to discuss and document key treatment decisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Assess and address patient and family's information needs and understanding of the disease, address gaps between reality and expectation, foster realistic hope and provide opportunity to explore prognosis and life expectancy, and preparedness for death</td>
</tr>
<tr>
<td>- Explore the patient's views on medications, tests, resuscitation, intensive care and preferred location of death</td>
</tr>
<tr>
<td>- If a patient makes any treatment decisions relevant to their current condition (i.e., provides consent), these decisions can be incorporated into their Plan of Treatment</td>
</tr>
<tr>
<td>- Review Goals of Care, and patient preferences regularly, particularly when there is a change in clinical status</td>
</tr>
</tbody>
</table>

### Screen for specific end of life psychosocial issues
- Assess and address patient and families' loss, grief and bereavement needs including anticipatory grief, past trauma or losses, preparing children (young children, adolescents, young adults), guardianship of children, death anxiety |
- Provide appropriate guidance, support and information to families, caregivers, and others, based on awareness of culture and needs, and make referrals to available resources and/or specialized services to address identified needs as required |
- Identify family members at risk for abnormal/complicated grieving and connect them proactively with bereavement resources

### Identify patients who could benefit from specialized palliative care services (consultation or transfer)
- As patient and family/caregivers needs increase and/or change over time consult with palliative care specialists and/or other providers with additional expertise, as required. Transfer care only if and when needs become more extensive or complex than the current team can handle |
- Discuss referral with the patient and their family/caregiver

### Proactively develop and implement a plan for expected death
- Explore place-of-death preferences and the resources required (e.g., home, hospice, palliative care unit, long term care or nursing home) to assess whether this is realistic |
- Prepare and support the family to understand what to expect, and plan for when a loved one is actively dying, including understanding probable symptoms, as well as the processes with death certification and how to engage funeral services |
- Discuss emergency plans with patient and family (including who to contact, and when to use or avoid Emergency Medical Services)

### Home care planning (if this is where care will be delivered)
- Contact the patient's primary care and home and community care providers and relevant specialist physicians to ensure an effective transfer of information related to their care. If the patient is transitioning from the hospital, this should include collaborating to develop a transition plan |
- Introduce patient and family to resources in community (e.g., respite, day hospice programs, volunteer services, support groups, etc.) |
- Connect with home and community care services early (not just in the last 2-4 weeks) |
- Ensure resources and services are in place to support the patient and their family/caregiver, and address identified needs |
- Anticipate/plan for pain and symptom management, including consideration for a Symptom Response Kit to facilitate access to pain, dyspnea, and delirium medication for emergency purposes |
- If the patient consents to withholding cardiopulmonary resuscitation, A ‘Do Not Resuscitate’ order must be documented in their medical record, and a Do Not Resuscitate Confirmation (DNR-C) Form should be completed. This form should be readily accessible in the home, to ensure that the patient’s wishes for a natural death are respected by Emergency Medical Services
Mucinous Epithelial Ovarian Cancer Treatment and Follow-up Pathway Map

At the time of death:
- Pronouncement of death
- Completion of death certificate
- Allow family members to spend time with loved one upon death, in such a way that respects individual rituals, cultural diversity and meaning of life and death
- Implement the pre-determined plan for expected death
- Arrange time with the family for a follow-up call or visit
- Provide age-specific bereavement services and resources
- Inform family of grief and bereavement resources/services
- Initiate grief care for family members at risk for complicated grief
- Encourage the bereaved to make an appointment with an appropriate health care provider as required

Bereavement Support and Follow-Up
- Offer psychoeducation and/or counseling to the bereaved
- Screen for complicated and abnormal grief (family members, including children)
- Consider referral of bereaved family member(s) and children to appropriate local resources, spiritual advisor, grief counselor, hospice and other volunteer programs depending on severity of grief

Patient Death

Provide opportunities for debriefing of care team, including volunteers